The Real Engine Behind Johnson & Johnson Stock’s Next Climb

While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.

After a substantial 62% run-up over the past year, Johnson & Johnson (JNJ) stock has spent the last few months catching its breath. It’s the kind of pause that makes you wonder: what, exactly, could power the next sustained move higher for a company this size? The answer, it turns out, might be hiding in plain sight.

Double-Digit Growth In Plain Sight

You probably saw that Johnson & Johnson reported operational sales growth of 5.6% in its latest quarter. Solid, but hardly the stuff of legend. But peel back one layer, the expected decline of its older top-selling drug, STELARA, and a completely different picture emerges. Excluding STELARA, management revealed the rest of the business “grew double digits in the quarter.” In fact, the core Innovative Medicine division, stripped of that one headwind, grew over 14%. That’s the kind of momentum that can quietly compound shareholder value while the market is looking elsewhere.

Where Is This From?

This isn’t a one-product story. It’s a portfolio hitting its stride. Look at TREMFYA, a treatment for Crohn’s disease and ulcerative colitis. It delivered “exceptional overall sales growth of 71% in the quarter,” accelerating from 64% growth in the prior quarter. Management notes it’s now the fastest-growing advanced therapy in its class. Alongside established powerhouses, new launches are already making their mark. ICOTYDE, a new oral treatment for psoriasis, has seen more than 11,000 patients start therapy (18,000 prescriptions) since its recent launch, a figure that jumped from just 1,500 prescriptions written a quarter ago. This pairing of a mature drug hitting a new gear and a new drug finding rapid adoption is a powerful combination for the company’s segment financials.

The MedTech Friction

Of course, not every part of the business is firing on all cylinders. Management was candid that in MedTech, results were “not to our standards in cardiovascular,” with the Abiomed heart pump business seeing a 2% decline. This is the friction in the J&J story, and it’s a real concern for some investors. We recently explored the dynamic of what management sees versus what the market is pricing in. But here’s the key: the growth in Innovative Medicine was so potent that the company still confidently raised its full-year sales guidance by $400 million. That’s a signal that the pharma engine is powerful enough to pull the whole train, even with one of the cars dragging its feet.

But for those focused on JNJ itself, the path forward seems increasingly clear. The debate over a temporary slowdown in one division risks obscuring the sheer commercial force of its drug pipeline. The real story here isn’t about a single quarter’s weakness, but the durable, accelerating strength that could keep this stock climbing for the long haul.

Where Do You Hunt For The Next Story Like This?

An opportunity like this only counts once it starts showing up in the numbers, and the first hard place it surfaces is management’s guidance. The moment a company can actually see the new revenue coming, it raises its forecast, and a raised forecast that the market is already rewarding is about the cleanest proof that a story like this is turning real. Dell Technologies (DELL), Fortinet (FTNT), and GE Vernova (GEV) are flashing exactly that signal right now. Our Guidance Momentum screen tracks every S&P 500 name where a rising forecast is already meeting real price momentum, so you can hunt for the next opportunity like this one while it is still early. And if you would rather own the whole theme than bet on this one name, a healthcare ETF like XLV holds the entire group.

Finding Winners Is Half The Job, Keeping The Gains Is The Other

Spotting the opportunity is the enjoyable half of investing; keeping what it earns is the half that compounds. How much damage any single position could do to your net worth is a question with a precise answer. The Trefis Wealth team computes it for investors professionally, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.